Find clinical trials for Non-Hodgkin Lymphoma in Hanyang, Seoul
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Non-Hodgkin Lymphoma trials near Hanyang, Seoul, KOR:
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...
Phase 1, Phase 2
Seoul, Korea, Republic of and 89 other locations
tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-0201 in adult patients with relapsed or refractory B-cell non...
Phase 1
Seoul, Korea, Republic of and 20 other locations
The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in pr...
Phase 3
Seoul, Korea, Republic of and 186 other locations
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary efficacy of VAY736 alone or in...
Phase 1
Seoul, Korea, Republic of and 9 other locations
Determine MTD based on the safety and tolerability of AT101 and the RP2D for patients with recurrent or non-reactive B-cell NHL....
Phase 1, Phase 2
Seoul, Seoul, South Korea
JNJ 67856633 when administered together in participants with B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leu...
Phase 1
Seoul, Korea, Republic of and 27 other locations
is focused on patients with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding ...
Phase 3
Seoul, Korea, Republic of and 57 other locations
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purp-...
Phase 2
Seoul, Seoul Teugbyeolsi, Korea, Republic of and 74 other locations
The main purpose of this study is to characterize safety and to determine the recommended phase 2 dose (RP2D) for JNJ-88998377 (Part A: Dose Escalati...
Phase 1
Seoul, Korea, Republic of and 17 other locations
targeting both cluster of differentiation (CD) CD19 and CD20 for the treatment of adult participants with relapsed or refractory B-Cell non- ...
Phase 1
Seoul, Korea, Republic of and 25 other locations
Clinical trials
Research sites
Resources
Legal